Skip to main content
main-content

Master Topic Page

News

18-10-2018 | Osteoarthritis | News

No pain relief with etanercept for hand OA

Treatment with the tumor necrosis factor inhibitor etanercept does not reduce pain at 24 weeks, compared with placebo, in patients with erosive hand osteoarthritis, preliminary trial data show.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213202

17-10-2018 | Psoriatic arthritis | News

News in brief

HIIT may be beneficial for PsA patients

Findings from a randomized trial indicate that high-intensity interval training may improve cardiorespiratory fitness in patients with psoriatic arthritis.

16-10-2018 | Adult-onset Still's disease | News

Further investigation of tocilizumab may be warranted in adult-onset Still’s disease

The interleukin-6 inhibitor tocilizumab may improve systemic symptoms and reduce the need for glucocorticoids among patients with adult-onset Still’s disease refractory to glucocorticoid therapy, suggest findings from a small randomized trial.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213920

15-10-2018 | Juvenile idiopathic arthritis | News

Response to canakinumab sustained for up to 5 years in children with sJIA

Response to canakinumab therapy is sustained or even improved for up to 5 years in children with systemic juvenile idiopathic arthritis, with no new safety signals, according to the results of a long-term extension study published in the Annals of the Rheumatic Diseases.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213150

13-07-2018 | Juvenile idiopathic arthritis | Podcast | Audio

Transitioning from pediatric to adult rheumatology care

In this medwireNews podcast, we talk to Editorial Board member Sangeeta Sule about how patients with juvenile arthritis transition from pediatric to adult care, the challenges associated with this transition, and how the process can be improved.

26-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Trial results on upadacitinib for the treatment of RA

Roy Fleischmann comments on the results of the SELECT-MONOTHERAPY and SELECT-NEXT trials, which provide further evidence for the benefits of upadacitinib in patients with RA (6:18).

Read the accompanying news story

19-06-2018 | Psoriatic arthritis | EULAR 2018 | Video

Expert commentary: Low rates of radiographic progression with secukinumab treatment in PsA patients

Douglas Veale comments on study results showing that secukinumab-treated PsA patients have low rates of radiographic progression regardless of prior TNF inhibitor exposure or concomitant methotrexate treatment (2:45).

Read the accompanying news story

image credits